Peptide Therapeutics Market Size To Rake USD 76.83 Bn By 2032

Published Date : 29 Aug 2023

The global peptide therapeutics market size surpassed USD 43.11 billion in 2022 and it is expected to rake around USD 76.83 billion by 2032, poised to grow at a CAGR of 5.94% during the forecast period 2023 to 2032. Investments in the global peptide therapeutics market are increasing with discoveries of novel peptide conjugates.

Peptide Therapeutics Market Size and Growth Rate From 2023 To 2032

Market Overview:

All living organisms naturally produce peptides, and peptide therapeutics mimic natural peptides to perform multiple functions. Peptide therapeutics offer peptide replacement. Peptide therapeutics are widely used to promote weight loss and muscle building. Such peptides are used to treat cancer, diabetes, heart health issues, gastrointestinal disorders, neurological disorders, and other metabolic disorders. Healthcare experts often prescribe peptide therapeutics for aiding infective disease as peptides directly inhibit the replication cycle by targeting the virus. Thus, peptide therapeutics are used as an antiviral for flu and hepatitis.

Peptide therapeutics are relatively safe and highly preferred as they rarely show side effects on the human body. Thus, peptide therapeutics hold the potential to be used to treat multiple health conditions. Peptide therapeutics are available in innovative and generic types. However, the increased cost of treatment of targeted diseases has boosted the discovery and development of generic peptide therapeutics. Hospitals, retail and online pharmacies are significant distributors of peptide drugs. Multiple standard synthesis technologies are present in the global peptide therapeutics market, such as solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS) & hybrid technology.

The COVID-19 pandemic positively impacted the global peptide therapeutics market as multiple peptide drugs were involved in the treatment of COVID-19 infection. The global market is expected to witness noticeable growth during the forecast period of 2023-2032, owing to the advancements in the global biopharmaceutical industry. The predicted significant market growth during the forecast period will be the increased discoveries of multifunctional peptide conjugates.

Report Highlights:

  • North America dominates the global peptide therapeutics market; Asia Pacific is the fastest-growing region and is anticipated to show significant growth during the forecast period. 
  • The parenteral route of administration segment is leading in the global peptide therapeutics market.
  • The increasing cases of cancer across the globe have boosted the demand for peptide drugs used in cancer treatment, fueling the market's growth.
  • Generic peptide drugs are gaining demand across the globe as they are cost-effective.

Peptide Therapeutics Market Report Scope:

Report Coverage Details
Market Revenue in 2023 USD 45.67 Billion
Projected Forecast Revenue in 2032 USD 76.83 Billion
Growth Rate from 2023 to 2032 CAGR of 5.94%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Regional Snapshot:

North America dominates the global peptide therapeutics market and is expected to maintain growth during the forecast period. Increasing cases of cancer and infectious diseases primarily propel the market's growth in North America. The discovery of efficient and faster peptide drugs in the region, owing to the contribution of major key players, has boosted the market's growth. The broad support offered by several governments for the discovery and development of newer peptide therapeutics during the COVID-19 pandemic has shown a noticeable boost in the market for North America. Major key players in North America that contribute to the growth of the peptide therapeutics market are Eli Lilly & Company, Pfizer Inc., Bachem Holding AG, CirclePharma Inc.& Sanofi SA.

The rapid adoption of peptide therapeutics by the healthcare sector in Europe has fueled the market's growth. Europe acquires a significant revenue share in the global peptide therapeutics market and holds the potential to grow during the forecast period. Peptides are widely applied as targeted anti-cancer drugs in the region. GlaxoSmithKline plc., Astra Zeneca Plc. And SiegFried Holdings AG is a crucial player in the European peptide therapeutics market.

Asia Pacific is the fastest-growing region in the global peptide therapeutics market. The biopharma industry's overall expansion is driving the peptide therapeutics market growth in Asia Pacific. Rising healthcare expenditures and the surging need for advanced peptide therapies have boosted the research and development activities in the Asia Pacific. The market outlook in Asia Pacific is impressive owing to the increased preference for peptide therapeutics over biological therapeutics. China, India, and Japan are considered major contributors to the market growth in Asia Pacific. The presence of significant peptide product manufacturers in China has positively impacted the development of the peptide therapeutics market in the Asia Pacific. A few prominent peptide product manufacturers in the country are Wuhan Senwayer Century Chemical Co Ltd., Xi'an Sheerherb Biological Technology Co Ltd., Beijing Mesochem Technology Co Ltd., and Shenzen Biolink Biotechnology Ltd.

Market Dynamics:


Increasing deployment of peptide drugs in the cancer treatment

Peptide drugs are used in the treatment of various chronic diseases. Considering the rapidly increasing chronic disease and cancer treatment, peptide therapeutics are considered one of the most potent drugs available. Peptide therapeutics offer better penetrability and minimal immunogenicity, which make them ideal therapeutics for cancer treatment. Peptide therapeutics specifically target cancer cells. Peptide drugs are widely used in prostate and breast cancer treatment as hormonal therapy. Such benefits associated with peptide therapeutics have fueled the research and development (R&D) activities and investments in the market and promoted the discovery of effective and faster novel peptide drugs for cancer treatment.

Moreover, the rising awareness about the side effects caused by prolonged chemotherapy and other cancer treatments has boosted the demand for peptide therapeutics. The advantages of peptide therapeutics promise a novel approach in the global market which propels the market's growth. Thus, deploying peptide drugs in cancer treatment is a driving factor for developing the global peptide therapeutics market.


High cost associated with peptide therapeutics

The excessive cost associated with peptide therapeutics limits the growth of the market. High screening procedures, product purity process, and overall manufacturing process of peptide therapeutics make the drugs costly. Innovative peptides are more expensive than conventional drugs to produce. Along with this, the substandard quality of peptide therapeutics led to the excessively priced peptide drugs. The excessive cost factor has affected the reach of peptide drugs in underdeveloped or economically weak countries. Such factors adversely affect the market's growth and are seen as a major restraining factor. However, the surging research activities to discover generic peptide therapeutics will likely combat this restraint in the upcoming years.


Rising research and development activities for novel peptide drug discovery

The peptide therapeutics market has been experiencing considerable growth for a decade. The increasing deployment of peptide drugs from the healthcare sector across the globe demands more effective and short peptide drugs in the market. Researchers and biopharmaceutical companies are involved in research and development (R&D) activities that offer higher efficiency and faster absorption for targeted diseases and health issues. The boost in R&D activities is directly connected to the increase in investments in the global peptide therapeutics market. Increased investments by key players in research & development activities promote the advancement of the overall industry. Along with this, several governments are supporting the discovery and development of generic peptide drugs, which subsequently brings lucrative opportunities for investors, key players, and researchers involved in the market to grow. 


The risk of side effects caused by the peptide drugs

Peptide drugs promote multiple health benefits. On the other hand, the risk of side effects caused by peptide therapeutics creates an obstacle to the growth of the global market. The overdose or misuse of peptide drugs can show adverse effects on the body. Elevated blood sugar levels, skin damage, numb hands and feet, increased appetite, and upset stomach are a few common side effects caused due to overdose of peptide drugs. Pregnant, nursing, or breastfeeding women are more vulnerable to the side effects caused by peptide drugs. However, the regulations imposed by several governments on the sale of peptide drugs are likely to overcome this challenge. For example, peptide drugs are regulated under the FD&C act in the United States.

Recent Developments:

  • In December 2022, Egypt-based Roche Diagnostics launched an initiative named 'Peptide for Life.' This initiative focuses on better lab discovery of peptides used to treat heart issues.
  • In December 2022, a famous medical spa, Liquivida, opened a new medical wellness center in Middletown. The center offers peptide therapy for weight loss. The newly opened wellness center also provides IV therapy, blood analysis services, and hormonal replacement therapy.
  • In November 2022, a global radiotherapeutics company, Full-Life Technologies, announced the acquisition of New Jersey-based Focus-X Therapeutics. This acquisition will provide Full-Life Technologies with a second innovative peptide discovery-focused platform.
  • In July 2022, a global biopharmaceutical company, Amytrx Therapeutics, announced a strategic partnership with Ambio Pharm. The partnership aims to expand the potential of Amytrx anti-inflammatory human peptides.

Major Key Players:

  • Eli Lilly & Company
  • Amgen Inc.
  • Pfizer, Inc.
  • Ever Neuro Pharma GmbH
  • Bausch Health
  • Abbvie

Market Segmentation:

By Application

  • Gastrointestinal Disorder
  • Metabolic Disorder
  • Neurological Disorder
  • Cancer 
  • Others

By Type

  • Generic
  • Innovative 

By Route of Administration

  • Oral
  • Parenteral
  • Pulmonary
  • Mucosal
  • Others 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Drug Stores

By Synthesis Technology

  • Solid Phase peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333